PDF(Pubmed)
Abstract：
UNASSIGNED: Heart failure (HF) is a chronic condition associated with substantial mortality and hospitalisation, resulting in costly inpatient visits. The healthcare systems of several countries, including Vietnam, experience considerable difficulty in dealing with the enormous fiscal burden presented by HF. This study aims to analyse the direct medical costs associated with HF inpatient treatment from the hospital perspective.
UNASSIGNED: This study retrospectively analysed the electronic medical records of patients diagnosed with HF from 2018 to 2021 at Military Hospital 175 in Vietnam. The sample consisted of 906 hospitalised patients (mean age: 71.2 ± 14.1 years). The financial impact of HF was assessed by examining the direct medical expenses incurred by the healthcare system, and the costs of pharmaceutical categories used in treatment were explored.
UNASSIGNED: The cumulative economic burden of HF from 2018 to 2021 was US$1,068,870, with annual costs ranging from US$201,670 to US$443,831. Health insurance covered 72.7% of these costs. Medications and infusions, and medical supplies accounted for the largest expenses, at 29.8% and 22.1%, respectively. The medication HF group accounted for 13.01% of these expenses, of which the costliest medications included nitrates (2.57%), angiotensin II receptor blockers (0.51%), ivabradine (0.39%), diuretics (0.24%), and mineralocorticoid receptor antagonists (0.23%). Comorbidities and the length of hospital stay significantly influenced annual treatment costs.
UNASSIGNED: The study reveals that HF significantly impacts Vietnam\'s healthcare system and citizens, requiring a comprehensive understanding of its financial implications and efficient management of medical resources for those diagnosed. This study highlights the substantial economic burden of HF on Vietnam\'s healthcare system, with medication costs, particularly antithrombotic drugs, representing the largest expense. Most healthcare costs were covered by health insurance, and expenses were significantly influenced by comorbidity and length of hospital stay. These findings can inform healthcare policy, resource allocation and optimise management strategies in Vietnam.
UNASSIGNED: This study retrospectively analysed the electronic medical records of patients diagnosed with HF from 2018 to 2021 at Military Hospital 175 in Vietnam. The sample consisted of 906 hospitalised patients (mean age: 71.2 ± 14.1 years). The financial impact of HF was assessed by examining the direct medical expenses incurred by the healthcare system, and the costs of pharmaceutical categories used in treatment were explored.
UNASSIGNED: The cumulative economic burden of HF from 2018 to 2021 was US$1,068,870, with annual costs ranging from US$201,670 to US$443,831. Health insurance covered 72.7% of these costs. Medications and infusions, and medical supplies accounted for the largest expenses, at 29.8% and 22.1%, respectively. The medication HF group accounted for 13.01% of these expenses, of which the costliest medications included nitrates (2.57%), angiotensin II receptor blockers (0.51%), ivabradine (0.39%), diuretics (0.24%), and mineralocorticoid receptor antagonists (0.23%). Comorbidities and the length of hospital stay significantly influenced annual treatment costs.
UNASSIGNED: The study reveals that HF significantly impacts Vietnam\'s healthcare system and citizens, requiring a comprehensive understanding of its financial implications and efficient management of medical resources for those diagnosed. This study highlights the substantial economic burden of HF on Vietnam\'s healthcare system, with medication costs, particularly antithrombotic drugs, representing the largest expense. Most healthcare costs were covered by health insurance, and expenses were significantly influenced by comorbidity and length of hospital stay. These findings can inform healthcare policy, resource allocation and optimise management strategies in Vietnam.
摘要：
心力衰竭（HF）是一种与大量死亡率和住院有关的慢性疾病，导致昂贵的住院就诊。几个国家的医疗系统，包括越南,在处理HF带来的巨大财政负担方面经历了相当大的困难。本研究旨在从医院角度分析与HF住院治疗相关的直接医疗费用。
■这项研究回顾性分析了2018年至2021年在越南军事医院175诊断为HF的患者的电子病历。样本包括906名住院患者(平均年龄:71.2±14.1岁)。通过检查医疗保健系统产生的直接医疗费用来评估HF的财务影响，并探讨了用于治疗的药物类别的成本。
■从2018年到2021年，HF的累计经济负担为1,068,870美元，每年的成本从201,670美元到443,831美元不等。健康保险涵盖了这些费用的72.7%。药物和输液，医疗用品占最大的开支，分别为29.8%和22.1%，分别。药物HF组占这些费用的13.01%，其中最昂贵的药物包括硝酸盐(2.57%)，血管紧张素II受体阻滞剂（0.51%），伊伐布雷定（0.39%），利尿剂（0.24%），盐皮质激素受体拮抗剂（0.23%）。合并症和住院时间显著影响年治疗费用。
■研究表明，HF对越南的医疗保健系统和公民产生重大影响，需要全面了解其财务影响，并为被诊断的人有效管理医疗资源。这项研究强调了HF对越南医疗系统的巨大经济负担，药物费用，特别是抗血栓药物，代表最大的开支。大多数医疗费用由医疗保险支付，费用受合并症和住院时间的影响显著。这些发现可以为医疗保健政策提供信息，越南的资源分配和优化管理策略。
■这项研究回顾性分析了2018年至2021年在越南军事医院175诊断为HF的患者的电子病历。样本包括906名住院患者(平均年龄:71.2±14.1岁)。通过检查医疗保健系统产生的直接医疗费用来评估HF的财务影响，并探讨了用于治疗的药物类别的成本。
■从2018年到2021年，HF的累计经济负担为1,068,870美元，每年的成本从201,670美元到443,831美元不等。健康保险涵盖了这些费用的72.7%。药物和输液，医疗用品占最大的开支，分别为29.8%和22.1%，分别。药物HF组占这些费用的13.01%，其中最昂贵的药物包括硝酸盐(2.57%)，血管紧张素II受体阻滞剂（0.51%），伊伐布雷定（0.39%），利尿剂（0.24%），盐皮质激素受体拮抗剂（0.23%）。合并症和住院时间显著影响年治疗费用。
■研究表明，HF对越南的医疗保健系统和公民产生重大影响，需要全面了解其财务影响，并为被诊断的人有效管理医疗资源。这项研究强调了HF对越南医疗系统的巨大经济负担，药物费用，特别是抗血栓药物，代表最大的开支。大多数医疗费用由医疗保险支付，费用受合并症和住院时间的影响显著。这些发现可以为医疗保健政策提供信息，越南的资源分配和优化管理策略。
